Calyxt, Inc. CLXT
We take great care to ensure that the data presented and summarized in this overview for Calyxt, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLXT
Top Purchases
Top Sells
About CLXT
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Insider Transactions at CLXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2025
|
Rory B Riggs |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
4,050,000
+10.96%
|
$0
$0.01 P/Share
|
|
Jun 05
2025
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
5,714,286
+35.17%
|
$5,714,286
$1.75 P/Share
|
|
May 22
2025
|
Jean Pierre Jules Lehmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,490
+50.0%
|
-
|
|
May 22
2025
|
Gerhard Prante Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,490
+44.7%
|
-
|
|
Mar 24
2025
|
Noel Sauer SVP, Research |
BUY
Grant, award, or other acquisition
|
Direct |
11,750
+10.02%
|
-
|
|
Mar 24
2025
|
Jason Stokes CLO, Gen Csl & Secy |
BUY
Grant, award, or other acquisition
|
Direct |
28,250
+18.12%
|
-
|
|
Mar 24
2025
|
Carlo Broos Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
28,250
+21.61%
|
-
|
|
Mar 24
2025
|
Gregory Francis William Gocal Chief Scientific Officer & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+13.8%
|
-
|
|
Mar 24
2025
|
Peter Beetham President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
125,500
+19.81%
|
-
|
|
Feb 25
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-12.98%
|
$1,150
$1.92 P/Share
|
|
Feb 24
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-11.49%
|
$2,300
$2.07 P/Share
|
|
Feb 21
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-10.31%
|
$2,300
$2.2 P/Share
|
|
Feb 20
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-9.34%
|
$2,300
$2.35 P/Share
|
|
Feb 19
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-8.55%
|
$2,300
$2.58 P/Share
|
|
Feb 18
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
2,300
-7.59%
|
$4,600
$2.52 P/Share
|
|
Feb 14
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-6.8%
|
$2,300
$2.6 P/Share
|
|
Feb 13
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-6.37%
|
$2,300
$2.53 P/Share
|
|
Feb 12
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-5.99%
|
$2,300
$2.45 P/Share
|
|
Feb 11
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-5.65%
|
$2,300
$2.48 P/Share
|
|
Feb 10
2025
|
Gerhard Prante Director |
SELL
Open market or private sale
|
Direct |
1,150
-5.35%
|
$2,300
$2.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 6.3M shares |
|---|---|
| Conversion of derivative security | 1.39M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 4.05M shares |
| Conversion of derivative security | 1.39M shares |
|---|---|
| Open market or private sale | 80.8K shares |